Compare TNON & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNON | BRTX |
|---|---|---|
| Founded | 2012 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Managed Health Care |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 3.1M |
| IPO Year | 2021 | 2015 |
| Metric | TNON | BRTX |
|---|---|---|
| Price | $2.27 | $1.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $44.38 | ★ $160.00 |
| AVG Volume (30 Days) | ★ 255.9K | 29.9K |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.90 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,944,000.00 | $81,000.00 |
| Revenue This Year | $46.86 | N/A |
| Revenue Next Year | $63.99 | $383.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 20.35 | N/A |
| 52 Week Low | $2.40 | $0.14 |
| 52 Week High | $45.50 | $34.00 |
| Indicator | TNON | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.65 | 32.82 |
| Support Level | N/A | $1.28 |
| Resistance Level | $4.18 | $2.93 |
| Average True Range (ATR) | 0.22 | 0.18 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 1.94 | 23.41 |
Tenon Medical Inc is a medical device company that has minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.